Roper stock slips again after outlook miss; Deltek in focus as U.S. funding deadline nears
28 January 2026

Roper stock slips again after outlook miss; Deltek in focus as U.S. funding deadline nears

New York, Jan 28, 2026, 13:23 ET — Regular session

  • Roper shares dipped further, following a sharp decline linked to its 2026 guidance just a day earlier
  • The company reported weaker demand at Deltek, its government contracting software division
  • Traders are focused on Washington’s Jan. 31 funding deadline and a fresh wave of broker calls

Roper Technologies shares slipped roughly 2% in early afternoon trading Wednesday, as the software company’s 2026 forecast missed Wall Street expectations, pushing the stock lower.

This move matters since Tuesday’s guidance reset thrust Deltek back into the spotlight. Investors are now trying to figure out if the hiccup is just a blip or signals a prolonged slowdown in spending by U.S. agencies and government contractors.

Washington now faces yet another funding deadline this weekend, a risk Roper has flagged as a possible headwind for Deltek’s business.

Roper on Tuesday projected 2026 revenue growth around 8%, with adjusted earnings per share expected between $21.30 and $21.55—both figures coming in under analyst forecasts, per LSEG data cited by Reuters. The company also issued first-quarter adjusted EPS guidance of $4.95 to $5.00, falling short of estimates.

The company flagged weaker demand at Deltek, with Reuters noting management’s caution that future U.S. government shutdowns could weigh on the unit. Deltek saw a slowdown in September as agencies paused operations ahead of the latest shutdown.

Roper disclosed its fourth-quarter figures in an SEC filing, showing revenue at $2.06 billion and adjusted diluted EPS of $5.21. The company’s “adjusted” numbers exclude certain items it considers distortions to its core performance. https://www.sec.gov/Archives/edgar/data/882835/000088283526000003/a2025q4earningsrelease.htm

CEO Neil Hunn described the outlook as a “more appropriate and balanced” perspective, following a string of disappointing quarters tied to Deltek uncertainty, Reuters reported. https://www.reuters.com/technology/roper-forecasts-2026-revenue-profit-below-estimates-soft-government-contract-2026-01-27/

Broker updates keep coming. Stifel’s Brad Reback dropped the stock from “Buy” to “Hold” and slashed his price target from $550 to $385, according to StreetInsider. https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Roper+Industries+%28ROP%29+to+Hold%2C+Two+Consecutive+Misses+And+Few+Near-Term+Catalysts/25901351.html

The next move could swing either way. Should Deltek demand hold steady and agencies steer clear of another halt in contracting, investors might overlook a revenue miss. But if government activity stumbles again or license sales falter, the company’s hopes for a second-half rebound will face serious doubt.

Traders are focused on Capitol Hill as U.S. funding is set to expire at 12:01 a.m. Eastern on Saturday, Jan. 31. Reuters flagged the risk of a partial government shutdown if Congress fails to pass new funding.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
Previous Story

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Applied Digital stock price slides as APLD gives back Nvidia-CoreWeave rally — what investors watch next
Next Story

Applied Digital stock price slides as APLD gives back Nvidia-CoreWeave rally — what investors watch next